SCHEMBL2215859

SCHEMBL2215859

CC1CC(NC2=NCCO2)c2ccccc21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 15/20 0.56
ADRA2B P18089 14/20 0.56
ADRA2C P18825 14/20 0.56
ADRA1A P35348 6/20 0.56
CFB P00751 1/20 0.37
TAAR1 Q96RJ0 1/20 0.35
GMNN O75496 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
HTR1A P08908 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
TSHR P16473 1/20 0.34
OPRK1 P41145 1/20 0.34
HIF1A Q16665 1/20 0.34
NISCH Q9Y2I1 1/20 0.34
TAS1R3 Q7RTX0 1/20 0.34
TAS1R1 Q7RTX1 1/20 0.34
TAS1R2 Q8TE23 1/20 0.34
KCNN4 O15554 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6369306 0.76 ADRA2A (0.58) ADRA2AADRA2BADRA2CADRA1ACFB
SCHEMBL1723548 0.73 ADRA2B (0.84) ADRA2AADRA2BADRA2CADRA1A
SCHEMBL6897370 0.72 ADRA2A (0.54) ADRA2AADRA2BADRA2CADRA1ACFB
SCHEMBL10555827 0.71 ADRA2A (0.53) ADRA2AADRA2BADRA2CADRA1ACFB
SCHEMBL10554892 0.71 ADRA2A (0.53) ADRA2AADRA2BADRA2CADRA1ACFB
SCHEMBL1724062 0.71 ADRA2A (1.00) ADRA2AADRA2BADRA2CADRA1ATSHR
SCHEMBL2214992 0.71 POLB (0.44) TAAR1CYP1A2
SCHEMBL2216731 0.70 ADRA2A (0.57) ADRA2AADRA2BADRA2CADRA1ACFB
SCHEMBL13080425 0.68 SLC6A2 (0.53) CYP1A2CYP3A4CYP2D6CYP2C9TSHR
SCHEMBL16421280 0.68 SLC6A2 (0.53) CYP1A2CYP3A4CYP2D6CYP2C9TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110178143-A1 THERAPEUTIC COMPOUNDS ALLERGAN, INC. (US) 2011-07-21 US disclosed
US-20110178143-A1 THERAPEUTIC COMPOUNDS ALLERGAN, INC. (US) 2011-07-21 US disclosed
US-20110178143-A1 THERAPEUTIC COMPOUNDS ALLERGAN, INC. (US) 2011-07-21 US disclosed
CN-101855213-A Therapeutic compounds ALLERGAN INC 2010-10-06 CN disclosed
EP-2188261-A1 THERAPEUTIC COMPOUNDS Allergan, Inc. (US) 2010-05-26 EP disclosed
WO-2009023757-A1 THERAPEUTIC COMPOUNDS ALLERGAN, INC. (US) 2009-02-19 WO disclosed
WO-2009023757-A1 THERAPEUTIC COMPOUNDS ALLERGAN, INC. (US) 2009-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178143-A1 THERAPEUTIC COMPOUNDS GOT2, GOT1, ANXA5 ADRA2A 1550/4885ADRA2B 1943/4885ADRA2C 1223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.